N/A
N=41
Electroconvulsive Therapy Amplitude Titration
Major Depressive Disorder
Bottom Line
View on ClinicalTrials.gov: NCT04621786 ↗Enrolled (actual)
41
Serious AEs
3.5%
Results posted
Jun 2023
Primary outcome: Primary: Beta Coefficient From Linear Regression of Amplitude-determined Seizure (Independent Variable) and Ebrain (Dependent Variable) — -.0001054 beta coefficient from linear regression
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface (Device)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- University of New Mexico
- Primary completion
- Dec 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Beta Coefficient From Linear Regression of Amplitude-determined Seizure (Independent Variable) and Ebrain (Dependent Variable) |
-.0001054 | — |
Summary
This study is focused on advancing ECT treatment for older adults with depressive disorders by refining neuromodulation stimulus parameters to improve efficacy and cognitive safety.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of major depressive disorder
- Clinical indications for ECT with right unilateral electrode placement
- Right-handed
- Age range between 50 and 80 years
Exclusion Criteria
- Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease)
- Other psychiatric conditions (e.g., schizophrenia, bipolar disorder)
- Current drug or alcohol use disorder (except for nicotine); and 4) contraindications to MRI.
Data sourced from ClinicalTrials.gov (NCT04621786). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.